These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 32228012)

  • 1. Non-Reflex Defense Mechanisms of Upper Airway Mucosa: Possible Clinical Application.
    Pedan H; Janosova V; Hajtman A; Calkovsky V
    Physiol Res; 2020 Mar; 69(Suppl 1):S55-S67. PubMed ID: 32228012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nasal vaccines.
    Davis SS
    Adv Drug Deliv Rev; 2001 Sep; 51(1-3):21-42. PubMed ID: 11516777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthetic polyacrylate polymers as particulate intranasal vaccine delivery systems for the induction of mucosal immune response.
    Zaman M; Simerska P; Toth I
    Curr Drug Deliv; 2010 Apr; 7(2):118-24. PubMed ID: 20158484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intranasal formulations: promising strategy to deliver vaccines.
    Riese P; Sakthivel P; Trittel S; Guzmán CA
    Expert Opin Drug Deliv; 2014 Oct; 11(10):1619-34. PubMed ID: 24962722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intranasal delivery of nanoparticle-based vaccines.
    Marasini N; Skwarczynski M; Toth I
    Ther Deliv; 2017 Jan; 8(3):151-167. PubMed ID: 28145824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nasal and pulmonary vaccine delivery using particulate carriers.
    Jia Y; Krishnan L; Omri A
    Expert Opin Drug Deliv; 2015 Jun; 12(6):993-1008. PubMed ID: 25952104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Defending the mucosa: adjuvant and carrier formulations for mucosal immunity.
    Lawson LB; Norton EB; Clements JD
    Curr Opin Immunol; 2011 Jun; 23(3):414-20. PubMed ID: 21511452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Nasal vaccines].
    Kido H; Mizuno D; Takei T
    Nihon Rinsho; 2008 Oct; 66(10):1881-7. PubMed ID: 18939485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Upper respiratory tract immunity.
    Zuercher AW
    Viral Immunol; 2003; 16(3):279-89. PubMed ID: 14583144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Application of Mucoadhesive Chitosan Nanoparticles in Nasal Drug Delivery.
    Shim S; Yoo HS
    Mar Drugs; 2020 Nov; 18(12):. PubMed ID: 33260406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human immune responses elicited by an intranasal inactivated H5 influenza vaccine.
    Ainai A; van Riet E; Ito R; Ikeda K; Senchi K; Suzuki T; Tamura SI; Asanuma H; Odagiri T; Tashiro M; Kurata T; Multihartina P; Setiawaty V; Pangesti KNA; Hasegawa H
    Microbiol Immunol; 2020 Apr; 64(4):313-325. PubMed ID: 31957054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a novel adjuvanted nasal vaccine: C48/80 associated with chitosan nanoparticles as a path to enhance mucosal immunity.
    Bento D; Staats HF; Gonçalves T; Borges O
    Eur J Pharm Biopharm; 2015 Jun; 93():149-64. PubMed ID: 25818119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin 12 and innate molecules for enhanced mucosal immunity.
    Boyaka PN; Lillard JW; McGhee J
    Immunol Res; 1999; 20(3):207-17. PubMed ID: 10741861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mucosal immunity: overcoming the barrier for induction of proximal responses.
    McKenzie BS; Brady JL; Lew AM
    Immunol Res; 2004; 30(1):35-71. PubMed ID: 15258310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunoglobulin A (IgA) responses and IgE-associated inflammation along the respiratory tract after mucosal but not systemic immunization.
    Hodge LM; Marinaro M; Jones HP; McGhee JR; Kiyono H; Simecka JW
    Infect Immun; 2001 Apr; 69(4):2328-38. PubMed ID: 11254590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nasal lymphoid tissue, intranasal immunization, and compartmentalization of the common mucosal immune system.
    Wu HY; Russell MW
    Immunol Res; 1997; 16(2):187-201. PubMed ID: 9212364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cationic pullulan nanogel as a safe and effective nasal vaccine delivery system for respiratory infectious diseases.
    Nakahashi-Ouchida R; Yuki Y; Kiyono H
    Hum Vaccin Immunother; 2018; 14(9):2189-2193. PubMed ID: 29624474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modified pulmonary surfactant is a potent adjuvant that stimulates the mucosal IgA production in response to the influenza virus antigen.
    Mizuno D; Ide-Kurihara M; Ichinomiya T; Kubo I; Kido H
    J Immunol; 2006 Jan; 176(2):1122-30. PubMed ID: 16394001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bridging nanoplatform and vaccine delivery, a landscape of strategy to enhance nasal immunity.
    Teng Z; Meng LY; Yang JK; He Z; Chen XG; Liu Y
    J Control Release; 2022 Nov; 351():456-475. PubMed ID: 36174803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characteristics of nasal-associated lymphoid tissue (NALT) and nasal absorption capacity in chicken.
    Kang H; Yan M; Yu Q; Yang Q
    PLoS One; 2013; 8(12):e84097. PubMed ID: 24391892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.